Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

    By Global Biodefense StaffJanuary 10, 2023
    Share
    Facebook LinkedIn Reddit Email

    Goal is to add new medical countermeasure (MCM) against known and emerging viral respiratory threats

    ENA Respiratory has been awarded a $4.38 million agreement from the U.S. Department of Defense to support ongoing research and development of INNA-051, a clinical stage broad-spectrum antiviral innate immunomodulator, administered intranasally for the prophylaxis of respiratory viral infections and their complications.

    The agreement was awarded by the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Innovation Unit (DIU). Funding will support studies to develop an intranasal dry powder formulation of INNA-051 and scale-up manufacturing processes.

    “Populations at high risk of exposure or complications continue to be significantly affected by influenza, SARS-CoV-2, RSV and other respiratory viruses, driving increased hospitalizations and health care utilization,” said Christophe Demaison, Ph.D., co-founder and CEO of ENA Respiratory. “This agreement with the DoD recognizes the necessity of developing a broad-spectrum and fast acting treatment to combat these debilitating viruses, and studying its use across a range of critical populations.”

    The effort is expected to run for 12 months, paving the way to an Investigational New Drug (IND)-submission to the U.S. FDA aiming to support the Phase I bioequivalence study of an intranasal dry powder presentation of INNA-051. A dry powder formulation offers a number of advantages over the current spray solution formulation that will support deployment to distant or resource-limited settings and survival through the rigours of DoD logistics. INNA-051 was recently studied in a Phase 2a influenza challenge pre-exposure prophylaxis study, and results are expected soon. It was found to be well-tolerated in a Phase 1 study.

    ABOUT INNA-051

    INNA-051 is a potent innate immune TLR2/6 agonist. It is currently in clinical development for self-administered intranasal delivery to target the primary entry site of viral respiratory infections as most respiratory viruses, including SARS-CoV-2 and influenza, initially infect and replicate in nasal mucosa epithelial cells. Fast-acting and inducing a durable biologic response supporting weekly administration, INNA-051 works by recruiting innate immune cells and priming epithelial cells of the nasal mucosa to respond more quickly to infections, rapidly eliminating viruses and other pathogens before they spread throughout the body. INNA-051 and close analogues have been shown in preclinical studies to be effective against multiple respiratory viruses, including SARS-CoV-2, influenza (H1N1 and seasonal H3N2), and rhinovirus.

    Key features of INNA-051 intranasal administration include minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation which is known to be associated with fever in humans, durable immune response supporting weekly administration, and compatibility with vaccine and intranasal corticosteroids.

    Source: ENA Respiratory


    READ ALSO:

    Building Better Antivirals for the Next Pandemic

    NIAID to Create New Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern

    Texas Biomed Tapped for National ‘Dream Team’ Developing Antivirals Against Biothreats

    ATCC Announces Awards from DTRA Supporting Global Health and Biodefense

    Antivirals Awards Drug Development Editor Pick JPEO-CBRND Thermostability
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleHow Organ-on-a-chip Models Could Grease the Drug Development Pipeline
    Next Article Biodefense Headlines – 10 January 2023

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    Global Biodefense places cookies on your device to enable the best user experience. By using our website, you agree to placement of these cookies. To learn more, read our Privacy Policy.OKPrivacy Policy